McKesson Reports Fiscal Q2 2027 Results, Raises Guidance, and Announces Strategic Expansion

McKesson reported fiscal Q2 2027 revenue of $110.96 billion, up 8% year over year, and adjusted EPS of $11.68, above analyst estimates. The company raised its fiscal 2027 adjusted EPS guidance to $45.60–$46.40. McKesson extended its drug distribution agreement with CVS Health through June 2032 and plans to acquire about 49% of Option Care Health for $1.4 billion, subject to closing conditions. It also completed its acquisition of Precision Medicine Group on November 2, 2026, and reiterated plans to separate its medical-surgical solutions segment into an independent company.